Anti-Survivin antibodies | Miltenyi Biotec 130-106-741 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Miltenyi Biotec

product type :

antibody

product name :

Anti-Survivin antibodies

catalog :

130-106-741

quantity :

for 30 tests

clonality :

recombinant

host :

human

conjugate :

clone name :

REA459

reactivity :

human

application :

flow cytometry

product information

Item Name :

Anti-Survivin antibodies

Catalog Number :

130-106-741

Quantity :

for 30 tests

Target :

Survivin

Reactivity :

human

Applications :

Flow Cytometry

Primary / Secondary :

Primary

Host :

human

Conjugate/Tag/Label :

Format :

Antibodies are supplied in buffer containing stabilizer and 0.05% sodium azide.

Isotype :

recombinant human IgG1

Clone :

REA459

Clonality :

recombinant

Long text :

Clone REA459 recognizes the human survivin antigen, a member of the inhibitor of apoptosis (IAP) family. Survivin is also known as baculoviral IAP repeat-containing protein 5 (BIRC5) or apoptosis inhibitor 4 (API4). The survivin protein inhibits caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. Expression of survivin is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. It is expressed highly in most human tumors and fetal tissue, but is completely absent in terminally differentiated cells. Its overexpression has been demonstrated in breast and lung cancer, prostate, gastric, colon, bladder and esophageal carcinomas, osteosarcomas, and lymphomas. Overexpression of survivin was also found to be significantly associated with a poor prognosis and decreased survival rates in oral, breast, and colorectal cancers. Additional information: Clone REA459 displays negligible binding to Fc receptors.